Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of Scott Chappel, Ph.D., as its Chief Scientific Officer (CSO). Reporting to Chief Executive Officer Michel Detheux, Ph.D., Dr.Read more
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
- Two new appointments follow oversubscribed $75 million (€64 million) Series B financing and support next stage of iTeos’ growthRead more
- Oversubscribed financing round led by new U.S. investor MPM Capital
- Proceeds to support accelerated development of innovative next-generation immuno-oncology pipeline into the clinic and the company’s expansion into the U.S.
iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
Gosselies, Belgium– April 12, 2018 –iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it will present data for its A2Aantagonist and anti-TIGIT antibody programs in two abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting,Read more
Gosselies, Belgium – March 21, 2018 - iTeos Therapeutics is pleased to have been awarded the Trends Gazelles 2018 award for Wallonia. Trends Gazelles Ambassadors are fast-growing companies that have a significant positive impact on the competitiveness and business dynamics of their region.Read more